Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent ormetastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE

被引：0
|
作者：
Licitra, L. [1 ]
Even, C. [2 ]
Haddad, R. [3 ]
Tahara, M. [4 ]
Goswami, T. [5 ]
Franks, A. [6 ]
Emeribe, U. [7 ]
Jarkowski, A., III [5 ]
Melillo, G. [7 ]
Ferris, R. L. [8 ,9 ]
机构：
[1] Fdn IRCCS Inst Nazl Tumori, Head & Neck Canc Med Oncol Unit, Milan, Italy
[2] Inst Gustave Roussy, Head & Neck Oncol, Villejuif, France
[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[4] Natl Canc Ctr Hosp East, Head & Neck Med Oncol, Kashiwa, Chiba, Japan
[5] AstraZeneca, Immunooncol GMD, Gaithersburg, MD USA
[6] AstraZeneca, Clin Dev, Immunooncol, Gaithersburg, MD USA
[7] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[8] Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Pittsburgh, PA USA
[9] Univ Pittsburgh, Inst Canc, Canc Immunol Program, Pittsburgh, PA USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
341TiP
引用
收藏
页码：101 / 101
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of nivolumab (Nivo) in recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): A real-world data study
    Soto Castillo, J. J.
    Esteban Villarrubia, J.
    Alvarez Ballesteros, P.
    Garrido Lopez, P.
    Soria Rivas, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1438 - S1438
  • [32] Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study
    Zandberg, D.
    Algazi, A.
    Jimeno, A.
    Good, J. S.
    Fayette, J.
    Bouganim, N.
    Ready, N.
    Clement, P. M.
    Goswmi, T.
    Jarkowski, A.
    Armstrong, J. M.
    Asubonteng, K.
    Melillo, G.
    Mesia, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] ANALYSES OF HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    DeRosa, M.
    Cocks, K.
    Taylor, F.
    Bobiak, S.
    Garcia, Juarez A.
    Shaw, J. W.
    VALUE IN HEALTH, 2017, 20 (05) : A113 - A113
  • [34] Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) previously treated with platinum-based therapy
    Rottey, Sylvie
    Van Maanen, Aline
    Vandenbulcke, Jean-Marie
    Filleul, Bertrand
    Seront, Emmanuel
    Henry, Stefanie
    D'Hondt, Lionel A.
    Lonchay, Christophe
    Holbrechts, Stephane
    Boegner, Petra
    Brohee, Dany J.
    Dequanter, Didier
    Louviaux, Ingrid
    Sautois, Brieuc
    Whenham, Nicolas
    Berchem, Guy J.
    Vanderschueren, Brigitte
    Fontaine, Christel
    Schmitz, Sandra
    Machiels, Jean-Pascal H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Phase I dose-finding and pharmacokinetic study of IV vinflunine in combination with methotrexate in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) previously treated with platinum-based chemotherapy.
    Mailliez, Audrey
    Rolland, Frederic
    Tourani, Jean Marc
    Lafond, Cedrik
    Cupissol, Didier
    Isambert, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial
    Fayette, J.
    Bauman, J.
    Salas, S.
    Colevas, D.
    Even, C.
    Cupissol, D.
    Posner, M. R.
    Lefebvre, G.
    Saada-Bouzid, E.
    Bernadach, M.
    Seiwert, T.
    Pearson, A.
    Messouak, S.
    Cornen, S. L.
    Andre, P.
    Rotolo, F.
    Boyer-Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1450 - S1450
  • [37] TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC
    Even, C.
    Daste, A.
    Saada-Bouzid, E.
    Fayette, J.
    Kaminsky-Forrett, M-C.
    Zanetta, S.
    Prevost, A.
    Lefebvre, G.
    Borel, C.
    Cupissol, D.
    Huguet, F.
    Delord, J-P.
    Rotllan, N. Baste
    Delaye, J.
    Jallut, I.
    Vintonenko, N.
    Bourhis, J.
    Guigay, J.
    Texier, M.
    Auperin, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 380 - 380
  • [38] An analysis of toxicity in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving cetuximab, fluorouracil and cisplatin alone or with docetaxel in a phase II clinical trial (CeFCiD)
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher, J.
    Gruenwald, V
    Rethwisch, V
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2012, 35 : 153 - 153
  • [39] Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
    Psyrri, A.
    Fayette, J.
    Harrington, K.
    Gillison, M.
    Ahn, M. -J.
    Takahashi, S.
    Weiss, J.
    Machiels, J. -P.
    Baxi, S.
    Vasilyev, A.
    Karpenko, A.
    Dvorkin, M.
    Hsieh, C. -Y.
    Thungappa, S. C.
    Segura, P. P.
    Vynnychenko, I.
    Haddad, R.
    Kasper, S.
    Mauz, P. -S.
    Baker, V.
    He, P.
    Evans, B.
    Wildsmith, S.
    Olsson, R. F.
    Yovine, A.
    Kurland, J. F.
    Morsli, N.
    Seiwert, T. Y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 262 - 274
  • [40] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345